Business Description
Relay Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US75943R1023
Share Class Description:
RLAY: Ordinary SharesTotal Employee Number:
192Description
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 20.34 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.11 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 41.17 | |||||
Beneish M-Score | -2.61 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 95 | |||||
3-Year EBITDA Growth Rate | 13.9 | |||||
3-Year EPS without NRI Growth Rate | 15.8 | |||||
3-Year FCF Growth Rate | 13.5 | |||||
3-Year Book Growth Rate | -25.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 29.67 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 62.67 | |||||
9-Day RSI | 65.91 | |||||
14-Day RSI | 66.26 | |||||
3-1 Month Momentum % | -2.95 | |||||
6-1 Month Momentum % | 86.52 | |||||
12-1 Month Momentum % | 311.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 22.13 | |||||
Quick Ratio | 22.13 | |||||
Cash Ratio | 21.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.8 | |||||
Shareholder Yield % | -2.78 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -2776.6 | |||||
Net Margin % | -2554.14 | |||||
EBITDA Margin % | -2749.88 | |||||
FCF Margin % | -1998.53 | |||||
OCF Margin % | -1998.29 | |||||
ROE % | -42.56 | |||||
ROA % | -38.75 | |||||
ROIC % | -561.96 | |||||
3-Year ROIIC % | -12.74 | |||||
ROC (Joel Greenblatt) % | -648.19 | |||||
ROCE % | -44.09 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 307.01 | |||||
PB Ratio | 5.53 | |||||
Price-to-Tangible-Book | 5.52 | |||||
EV-to-EBIT | -11.71 | |||||
EV-to-Forward-EBIT | 17.48 | |||||
EV-to-EBITDA | -11.82 | |||||
EV-to-Revenue | 325.14 | |||||
EV-to-Forward-Revenue | 374.83 | |||||
EV-to-FCF | -16.27 | |||||
Price-to-GF-Value | 4.51 | |||||
| Price-to-Net-Current-Asset-Value | 5.89 | |||||
| Price-to-Net-Cash | 6.06 | |||||
Earnings Yield (Greenblatt) % | -8.54 | |||||
FCF Yield % | -5.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RLAY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Relay Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 10.677 | ||
| EPS (TTM) ($) | -1.57 | ||
| Beta | 2.1634 | ||
| 3-Year Sharpe Ratio | 0.45 | ||
| 3-Year Sortino Ratio | 0.81 | ||
| Volatility % | 63.46 | ||
| 14-Day RSI | 66.26 | ||
| 14-Day ATR ($) | 1.224384 | ||
| 20-Day SMA ($) | 17.6755 | ||
| 12-1 Month Momentum % | 311.39 | ||
| 52-Week Range ($) | 3.025 - 20.79 | ||
| Shares Outstanding (Mil) | 217.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Relay Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Relay Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 115 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 24 days | ||
| General meeting for 2026 | 2026-06-09 15:00 | 13.66 (-1.80%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 08:40 | 13.52 (-7.02%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 12:45 | 15.70 (-5.71%) | ||
| Relay Therapeutics Conference Call: Initial Clinical Data for Zovegalisib in Vascular Anomalies | 2026-05-19 08:00 | 12.10 (-1.06%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 13.09 (+5.23%) | ||
| Relay Therapeutics Conference Call: Zovegalisib Triplet Data in Breast Cancer | 2026-04-27 08:30 | 15.13 (-0.26%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-11 10:30 | 10.69 (+4.19%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 15:10 | 10.26 (+6.43%) |
Show
Entries
Relay Therapeutics Inc Frequently Asked Questions
What is Relay Therapeutics Inc(RLAY)'s stock price today?
The current price of RLAY is $18.73. The 52 week high of RLAY is $20.79 and 52 week low is $3.03.
When is next earnings date of Relay Therapeutics Inc(RLAY)?
The next earnings date of Relay Therapeutics Inc(RLAY) is 2026-08-07 Est..
Does Relay Therapeutics Inc(RLAY) pay dividends? If so, how much?
Relay Therapeutics Inc(RLAY) does not pay dividend.
Guru Commentaries on NAS:RLAY
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Relay Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers